Our technology enables researchers to predict human outcomes in the lab. We deliver accurate preclinical testing to help develop safer, more effective drugs.
Almost 90% of drugs that look promising in animal models fail when tested in humans, driving up the average cost and time of new drug development to $2.6 billion and 10 years or more. We deliver predictive human data in just weeks and at a fraction of the cost of in vivo studies.
Achieve the predictive readouts critical to your R&D success. We deliver clinically-relevant functional and structural metrics to improve success rates.
AxoSim's Nerve-on-a-Chip® platform facilitates prediction of both clinical neurotoxicity and efficacy in human neurodegenerative disease models earlier in the drug development pipeline.
The Mini Brain is a high quality 3D miniature brain organoid designed to serve as a human-relevant model in preclinical drug discovery.